Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Dasatinib shows promise as first treatment for chronic myelogenous leukemia

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib)

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New leukemia drug gives renewed hope to those battling drug resistance to the disease

Dasatinib offers new options for leukemia patients

Dasatinib offers new options for leukemia patients

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec